{"hashes":["NO5yd0bv","NO5yeEDj","NO5yeEbh","NO5yfkHg","NO5yf0Pu","NO5yeUDu","NO5yek\/v","NO5ye07m","NO5wfUHu","NO5yeEPg"],"after":1636851983,"sidebar_items":"
\n

\n Glax­o­SmithK­line\u2019s Vi­iV Health­care aims to shift HIV dai­ly pill think­ing in first DTC ads<\/a>\n <\/h3>\n<\/div>
\n

\n Spurned by FDA on an­oth­er im­munother­a­py, Agenus holds up ear­ly da­ta for CT­LA-4 drug across tu­mor types<\/a>\n <\/h3>\n<\/div>
\n

\n No­var­tis touts more late-stage da­ta for in­clisir­an, the once-cen­ter­piece heart drug spurned by the FDA<\/a>\n <\/h3>\n<\/div>
\n

\n The very slow roll of Bio­gen's Aduhelm: Neu­rol­o­gists weigh in on pa­tients, prac­tices and pay­ments amid on­go­ing me­dia storm<\/a>\n <\/h3>\n<\/div>
\n

\n Ac­cel­er­at­ed ap­provals un­der fire again as piv­otal tri­als typ­i­cal­ly take about as long as con­fir­ma­to­ry tri­als, re­search shows<\/a>\n <\/h3>\n<\/div>
\n

\n Mod­er­na dis­putes NIH claims on Covid-19 vac­cine patents, says it of­fered to make gov­ern­ment co-own­ers<\/a>\n <\/h3>\n<\/div>
\n

\n Covid-19 roundup: Mod­er­na notes high­er my­ocardi­tis risk for young males when com­pared to Pfiz­er's vac­cine; EMA signs off on Roche, Cell­tri­on mAb treat­ments<\/a>\n <\/h3>\n<\/div>
\n

\n NIH 'not done' fight­ing Mod­er­na over Covid vac­cine patents, di­rec­tor Fran­cis Collins says<\/a>\n <\/h3>\n<\/div>
\n

\n In­no­va­tion by Dis­rup­tion: Break­ing Si­los Be­tween R&D and Com­mer­cial Teams to Ad­vance New Treat­ments for Pa­tients<\/a>\n <\/h3>\n<\/div>
\n

\n Ap­pil­i's Covid-19 oral an­tivi­ral fails PhI­II tri­al; On­col­o­gy biotech Ankyra rais­es $45M in Se­ries B<\/a>\n <\/h3>\n<\/div>","articles":"
\n
\n \n
Cabenuva Ad (ViiV Healthcare)<\/span><\/div>\n<\/div>\n
\n
\n
\n <\/span>\n \n <\/a>\n <\/a>\n \n <\/div>\n \n
November 12, 2021 12:39 PM EST<\/div>\n
Pharma<\/span><\/a><\/div>
Marketing<\/span><\/a><\/div>\n<\/div>\n \n

Glax­o­SmithK­line\u2019s Vi­iV Health­care aims to shift HIV dai­ly pill think­ing in first DTC ads<\/h2>\n
\n
\n
<\/div>\n
\n

Beth Snyder Bulik<\/h3>\n

Senior Editor<\/h4>\n <\/div>\n<\/div>\n<\/div>\n \n
\n \n

For as long as there have been HIV medicines, the only options for patients have been daily pills — until this year that is. GlaxoSmithKline’s ViiV Healthcare approval for long-acting injectable Cabenuva in January marked a sudden change.<\/p>\n

Instead of people with HIV taking daily pills — a habit even reinforced in pop culture in film and other fictional depictions — there’s now a once-a-month injection option.<\/p>\n

\n \"Endpoints\n

Keep reading Endpoints with a free subscription<\/h3>\n

Unlock this story instantly and join 123,100+ biopharma pros reading Endpoints daily — and it's free. <\/p>\n

\n